KLRC1 and neoplasm: Therapeutic strategies targeting NKG2A, including blocking antibodies and competitive inhibitors of its ligand on tumor cells, are currently under investigation and will be discussed in detail in Section 4 on clinical applications of NK cell‐based therapies.